Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway
HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16 cervical cancer progression and the underlying mechanism. The transcript and protei...
Saved in:
Published in | Molecular medicine (Cambridge, Mass.) Vol. 27; no. 1; pp. 130 - 12 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central
19.10.2021
BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16
cervical cancer progression and the underlying mechanism.
The transcript and protein expression of Hsp90 in normal cervical and HPV16
cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16
cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated.
Hsp90 expression was up-regulated in HPV16
cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown.
In this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16
cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16
cervical cancers. |
---|---|
AbstractList | Abstract Background HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16+ cervical cancer progression and the underlying mechanism. Methods The transcript and protein expression of Hsp90 in normal cervical and HPV16+ cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16+ cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated. Results Hsp90 expression was up-regulated in HPV16+ cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown. Conclusion In this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16+ cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16+ cervical cancers. HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16+ cervical cancer progression and the underlying mechanism.BACKGROUNDHPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16+ cervical cancer progression and the underlying mechanism.The transcript and protein expression of Hsp90 in normal cervical and HPV16+ cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16+ cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated.METHODSThe transcript and protein expression of Hsp90 in normal cervical and HPV16+ cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16+ cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated.Hsp90 expression was up-regulated in HPV16+ cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown.RESULTSHsp90 expression was up-regulated in HPV16+ cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown.In this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16+ cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16+ cervical cancers.CONCLUSIONIn this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16+ cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16+ cervical cancers. HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic effect of heat shock protein 90 (Hsp90) knockdown on HPV16 cervical cancer progression and the underlying mechanism. The transcript and protein expression of Hsp90 in normal cervical and HPV16 cervical cancer tissues and cell lines were detected by qRT-PCR, immunohistochemistry staining and Western blot. Hsp90 knockdown clones were established using HPV16 cervical cancer cell line Caski and SiHa cells. The effect of Hsp90 knockdown on HER2/PI3K/AKT pathway and PD-L1 expression was characterized using qRT-PCR and Western blot analysis. Cell proliferation and migration were determined using MTT and transwell assays. Using mouse xenograft tumor model, the impact of Hsp90 knockdown and PD-L1 overexpression on tumor progression was evaluated. Hsp90 expression was up-regulated in HPV16 cervical cancer tissues and cells. Knockdown of Hsp90 inhibited proliferation and migration of Caski and SiHa cells. PD-L1 expression in cervical cancer tissues was positively correlated with Hsp90 expression, and Hsp90 regulated PD-L1 expression via HER2/PI3K/AKT signaling pathway. The results of mouse xenograft tumor model demonstrated Hsp90 knockdown suppressed tumor formation and overexpression of PD-L1 simultaneously eliminated the cancer-suppressive effect of Hsp90 knockdown. In this study, we demonstrated a promising tumor-suppressive effect of Hsp90 knockdown in HPV16 cervical cancers, and investigated the underlying molecular pathway. Our results suggested that Hsp90 knockdown holds great therapeutic potential in treating HPV16 cervical cancers. |
ArticleNumber | 130 |
Author | Li, Li-Jie Wang, Chen Zeng, Jie He, Si-Li |
Author_xml | – sequence: 1 givenname: Jie surname: Zeng fullname: Zeng, Jie – sequence: 2 givenname: Si-Li surname: He fullname: He, Si-Li – sequence: 3 givenname: Li-Jie surname: Li fullname: Li, Li-Jie – sequence: 4 givenname: Chen orcidid: 0000-0003-1780-3216 surname: Wang fullname: Wang, Chen |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34666670$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktvEzEUhS1URB_wB1ggL9mY-Dnj2SBVbSFRIxGhwoKNdcfjSV1NxoPtBPXf4zQtoiywZPnKPvc7ku85RUdjGB1Cbxn9wJiuZolRyimhnBFKhZaEv0AnTHFNRKX0UalpXRGmFDtGpyndFTVTUr1Cx0JWZdX0BP2Yp6mheDuR6NbbAbJLeHVJlgzngKcYNiE7PF99J1NIPvudw9bFnbcwYAtjqfHOA55ffeWz1UJcz86vb_AE-fYX3L9GL3sYknvzeJ6hb5-ubi7mZPnl8-LifEmsqppMhJQdWKsk64DpHpyCrlUSnGi5Ftz1rhbK1rrRQrW0qSrgtWM9t30DjbZWnKHFgdsFuDNT9BuI9yaANw8XIa4NxOzt4IzqJJV9r5WTnWzbTpdva3rKW1F1XHFVWB8PrGnbblxn3ZgjDM-gz19Gf2vWYWe04rLsAnj_CIjh59albDY-WTcMMLqwTYYrLSlTVb2Xvvvb64_J03CKQB8ENoaUouuN9RmyD3trPxhGzT4H5pADU6ZrHnJg9mz-T-sT_T9NvwFndLOf |
CitedBy_id | crossref_primary_10_1002_cam4_4828 crossref_primary_10_1007_s11596_024_2898_7 crossref_primary_10_1016_j_fitote_2024_106194 crossref_primary_10_1016_j_heliyon_2023_e16683 crossref_primary_10_1631_jzus_B2300457 crossref_primary_10_3390_ijms25136835 crossref_primary_10_3389_fphar_2022_806284 crossref_primary_10_1016_j_cellsig_2023_110639 crossref_primary_10_1080_02656736_2023_2259140 crossref_primary_10_3389_fonc_2023_1111778 crossref_primary_10_1016_j_intimp_2023_111077 crossref_primary_10_3389_fonc_2024_1488730 crossref_primary_10_1016_j_intimp_2024_113186 crossref_primary_10_1166_sam_2024_4597 crossref_primary_10_1007_s12013_024_01502_7 crossref_primary_10_3389_fphar_2023_1218467 crossref_primary_10_3892_mmr_2023_12933 crossref_primary_10_1016_j_ejmech_2024_116572 crossref_primary_10_3390_ijms23169317 crossref_primary_10_1016_j_abb_2022_109449 crossref_primary_10_1038_s41417_023_00682_3 crossref_primary_10_1186_s40779_024_00586_9 |
Cites_doi | 10.3390/cells9030632 10.1002/jcp.29590 10.1186/s13148-015-0084-2 10.1016/j.ejmech.2019.111725 10.1002/ijc.31357 10.1158/1541-7786.MCR-10-0534 10.1007/s00044-020-02534-3 10.1038/s41388-018-0252-x 10.1016/j.cell.2017.08.001 10.1128/mBio.02068-14 10.1158/0008-5472.CAN-14-3362 10.1007/978-1-4939-7477-1_28 10.1007/s13105-020-00730-8 10.1016/S0140-6736(16)32417-5 10.2174/1566524015666150114111745 10.1007/s00280-007-0522-8 10.1007/s00262-017-2017-8 10.1038/nature19328 10.1002/ijc.27739 10.1158/1940-6207.PREV-09-A74 10.1016/j.ejphar.2020.173355 10.1186/1471-2407-4-59 10.1038/sj.bjc.6601024 10.1158/1078-0432.CCR-13-2797 10.1038/nchembio.1335 10.1016/S2214-109X(19)30482-6 10.1084/jem.20160801 10.1016/j.bcp.2019.04.010 10.3389/fphar.2020.537265 10.1007/s12032-019-1299-4 10.1038/s41598-019-52652-1 10.1042/CBI20110473 10.21037/tlcr.2019.08.22 10.1155/2019/9675450 10.1186/s13058-020-01271-0 |
ContentType | Journal Article |
Copyright | 2021. The Author(s). The Author(s) 2021 |
Copyright_xml | – notice: 2021. The Author(s). – notice: The Author(s) 2021 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s10020-021-00384-2 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1528-3658 |
EndPage | 12 |
ExternalDocumentID | oai_doaj_org_article_5d404ff85e4d4bbd80389f02b36d2525 PMC8524852 34666670 10_1186_s10020_021_00384_2 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: ; grantid: 2020JJ5868 |
GroupedDBID | --- -ET 0R~ 123 29M 2WC 36B 5RE 5VS 7X7 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFO ACMJI ADBBV ADUKV AEGXH AENEX AFKRA AFPKN AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IH2 IHR ISR ITC KQ8 OK1 OVT P2P PHGZM PHGZT PIMPY RBZ RNS ROL RPM RSV SDH SJN SOJ SV3 TR2 UKHRP WOQ CGR CUY CVF ECM EIF NPM 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c569t-344dacc541da18fae5adb54ae3b2832efe735c789835b0966a27e1f2cf9a98cc3 |
IEDL.DBID | DOA |
ISSN | 1076-1551 1528-3658 |
IngestDate | Wed Aug 27 01:07:53 EDT 2025 Thu Aug 21 18:45:57 EDT 2025 Fri Jul 11 00:12:11 EDT 2025 Thu Apr 03 07:00:34 EDT 2025 Thu Apr 24 22:55:47 EDT 2025 Tue Jul 01 01:25:23 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Hsp90 PD-L1 HER2 Cervical cancer HPV16 |
Language | English |
License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c569t-344dacc541da18fae5adb54ae3b2832efe735c789835b0966a27e1f2cf9a98cc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-1780-3216 |
OpenAccessLink | https://doaj.org/article/5d404ff85e4d4bbd80389f02b36d2525 |
PMID | 34666670 |
PQID | 2584015672 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_5d404ff85e4d4bbd80389f02b36d2525 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8524852 proquest_miscellaneous_2584015672 pubmed_primary_34666670 crossref_citationtrail_10_1186_s10020_021_00384_2 crossref_primary_10_1186_s10020_021_00384_2 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20211019 |
PublicationDateYYYYMMDD | 2021-10-19 |
PublicationDate_xml | – month: 10 year: 2021 text: 20211019 day: 19 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Molecular medicine (Cambridge, Mass.) |
PublicationTitleAlternate | Mol Med |
PublicationYear | 2021 |
Publisher | BioMed Central BMC |
Publisher_xml | – name: BioMed Central – name: BMC |
References | K Kryeziu (384_CR20) 2019; 1871 VR Juneja (384_CR19) 2017; 214 Q Liu (384_CR25) 2020; 76 S Wang (384_CR34) 2018; 37 J-q Yuan (384_CR37) 2020 J Schwock (384_CR31) 2008; 61 S Daunys (384_CR10) 2019; 9 M Arbyn (384_CR3) 2020; 8 G Clifford (384_CR7) 2003; 89 XD Pei (384_CR30) 2020; 883 MB Cox (384_CR9) 2018 Z Hao (384_CR15) 2010; 37 A Chavez-Blanco (384_CR6) 2004; 4 L Hu (384_CR16) 2019 PB Calderon (384_CR5) 2019; 164 L-S Fu (384_CR11) 2020; 29 D Li (384_CR22) 2011; 9 M Atefi (384_CR4) 2014; 20 Y Wen (384_CR35) 2000; 60 G Gao (384_CR12) 2013; 132 NV Jordan (384_CR18) 2016; 537 D Xu (384_CR36) 2020; 9 W Huang (384_CR17) 2020; 235 Y-L Liou (384_CR24) 2015; 7 S-S Li (384_CR23) 2011; 26 M-X Zou (384_CR39) 2016; 8 Y Gao (384_CR13) 2018; 143 A Giatromanolaki (384_CR14) 2019; 36 L Zeng (384_CR38) 2015; 15 KJ Lastwika (384_CR21) 2016; 76 S Loibl (384_CR26) 2017; 389 W Wang (384_CR33) 2017; 66 J Codony-Servat (384_CR8) 2019; 8 S Mehndiratta (384_CR27) 2020; 185 M Ajiro (384_CR1) 2015 L Am (384_CR2) 2012; 36 L Mirabello (384_CR28) 2017; 170 PD Patel (384_CR29) 2013; 9 C Vernieri (384_CR32) 2020; 22 |
References_xml | – volume: 9 start-page: 632 year: 2020 ident: 384_CR36 publication-title: Cells doi: 10.3390/cells9030632 – volume: 235 start-page: 6942 year: 2020 ident: 384_CR17 publication-title: J Cell Physiol doi: 10.1002/jcp.29590 – volume: 7 start-page: 50 year: 2015 ident: 384_CR24 publication-title: Clin Epigenet doi: 10.1186/s13148-015-0084-2 – volume: 185 start-page: 111725 year: 2020 ident: 384_CR27 publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2019.111725 – volume: 8 start-page: 3274 year: 2016 ident: 384_CR39 publication-title: Am J Transl Res – volume: 143 start-page: 931 year: 2018 ident: 384_CR13 publication-title: Int J Cancer doi: 10.1002/ijc.31357 – volume: 9 start-page: 577 year: 2011 ident: 384_CR22 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-10-0534 – volume: 29 start-page: 942 year: 2020 ident: 384_CR11 publication-title: Med Chem Res doi: 10.1007/s00044-020-02534-3 – volume: 37 start-page: 4164 issue: 30 year: 2018 ident: 384_CR34 publication-title: Oncogene doi: 10.1038/s41388-018-0252-x – volume: 170 start-page: 1164 year: 2017 ident: 384_CR28 publication-title: Cell doi: 10.1016/j.cell.2017.08.001 – year: 2015 ident: 384_CR1 publication-title: MBio doi: 10.1128/mBio.02068-14 – volume: 76 start-page: 227 year: 2016 ident: 384_CR21 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-3362 – start-page: 397 volume-title: Chaperones year: 2018 ident: 384_CR9 doi: 10.1007/978-1-4939-7477-1_28 – volume: 76 start-page: 279 year: 2020 ident: 384_CR25 publication-title: J Physiol Biochem doi: 10.1007/s13105-020-00730-8 – volume: 389 start-page: 2415 year: 2017 ident: 384_CR26 publication-title: Lancet doi: 10.1016/S0140-6736(16)32417-5 – volume: 1871 start-page: 240 year: 2019 ident: 384_CR20 publication-title: Biochim Biophys Acta (BBA) – volume: 15 start-page: 38 year: 2015 ident: 384_CR38 publication-title: Curr Mol Med doi: 10.2174/1566524015666150114111745 – volume: 61 start-page: 669 year: 2008 ident: 384_CR31 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-007-0522-8 – volume: 66 start-page: 1379 year: 2017 ident: 384_CR33 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-017-2017-8 – volume: 537 start-page: 102 year: 2016 ident: 384_CR18 publication-title: Nature doi: 10.1038/nature19328 – volume: 60 start-page: 6841 year: 2000 ident: 384_CR35 publication-title: Cancer Res – volume: 132 start-page: 882 year: 2013 ident: 384_CR12 publication-title: Int J Cancer doi: 10.1002/ijc.27739 – volume: 37 start-page: 74 year: 2010 ident: 384_CR15 publication-title: Cancer Res Prev Treat doi: 10.1158/1940-6207.PREV-09-A74 – volume: 883 start-page: 173355 year: 2020 ident: 384_CR30 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2020.173355 – volume: 4 start-page: 1 year: 2004 ident: 384_CR6 publication-title: BMC Cancer doi: 10.1186/1471-2407-4-59 – volume: 89 start-page: 101 year: 2003 ident: 384_CR7 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601024 – volume: 20 start-page: 3446 year: 2014 ident: 384_CR4 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-2797 – volume: 9 start-page: 677 year: 2013 ident: 384_CR29 publication-title: Nat Chem Biol doi: 10.1038/nchembio.1335 – volume: 8 start-page: e191 year: 2020 ident: 384_CR3 publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(19)30482-6 – volume: 214 start-page: 895 year: 2017 ident: 384_CR19 publication-title: J Exp Med doi: 10.1084/jem.20160801 – volume: 26 start-page: 1573 year: 2011 ident: 384_CR23 publication-title: Oncol Rep – volume: 164 start-page: 177 year: 2019 ident: 384_CR5 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2019.04.010 – year: 2020 ident: 384_CR37 publication-title: Front Pharmacol doi: 10.3389/fphar.2020.537265 – volume: 36 start-page: 76 year: 2019 ident: 384_CR14 publication-title: Med Oncol doi: 10.1007/s12032-019-1299-4 – volume: 9 start-page: 1 year: 2019 ident: 384_CR10 publication-title: Sci Rep doi: 10.1038/s41598-019-52652-1 – volume: 36 start-page: 893 year: 2012 ident: 384_CR2 publication-title: Cell Biol Int doi: 10.1042/CBI20110473 – volume: 8 start-page: 340 year: 2019 ident: 384_CR8 publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr.2019.08.22 – year: 2019 ident: 384_CR16 publication-title: Oxid Med Cell Longev doi: 10.1155/2019/9675450 – volume: 22 start-page: 1 year: 2020 ident: 384_CR32 publication-title: Breast Cancer Res doi: 10.1186/s13058-020-01271-0 |
SSID | ssj0021545 |
Score | 2.4662776 |
Snippet | HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to investigate the therapeutic... Abstract Background HPV16 is the predominant cancer-causing strain that is responsible for over 50% of all cervical cancers. In this study, we aim to... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 130 |
SubjectTerms | Animals B7-H1 Antigen - genetics B7-H1 Antigen - metabolism Cell Line, Tumor Cervical cancer Female Gene Expression Regulation, Neoplastic Gene Knockdown Techniques - methods HER2 HPV16 Hsp90 HSP90 Heat-Shock Proteins - genetics HSP90 Heat-Shock Proteins - metabolism Human papillomavirus 16 - physiology Humans Mice Mice, Inbred BALB C Mice, Nude Middle Aged Papillomavirus Infections - genetics Papillomavirus Infections - metabolism Papillomavirus Infections - virology PD-L1 Phosphatidylinositol 3-Kinases - metabolism Proto-Oncogene Proteins c-akt - metabolism Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Reverse Transcriptase Polymerase Chain Reaction Signal Transduction - genetics Transferases - genetics Transferases - metabolism Uterine Cervical Neoplasms - genetics Uterine Cervical Neoplasms - metabolism Uterine Cervical Neoplasms - virology Xenograft Model Antitumor Assays - methods |
Title | Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34666670 https://www.proquest.com/docview/2584015672 https://pubmed.ncbi.nlm.nih.gov/PMC8524852 https://doaj.org/article/5d404ff85e4d4bbd80389f02b36d2525 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9swEBbtlkIvpe-m3QYVeisith6WfGy2WdzXEkK3hL0IPelCcUIeW_bfV2M5YVNKe-nFB1u2xMzI8w2a-QahNyyGBBIoI1RFRzh1lNTSO1I5JaWIjHkBBc5fzqrmnH-ci_mNVl-QE5bpgbPgRsLzgseoROCeW-sVMMLFglpWeSpox16afN4umOpDLQAGOduwIgAKduUyqoKiOQiZIDUBjsU4oQcuqWPu_xPc_D1r8oYbOn2A7vf4Eb_L636IboX2EbqbO0peP0YXzXpZF3i7JKvcZD6s8fQ9-VzizQIvu9S7gJvpN5KTta4Cdt3PIn3Sgf5X-OrS4GYyo6PpB_ZplCAghqbFP831E3R-Ovl60pC-fQJxoqo3hHHujXOCl96UKpogjLeCm8As9CcKMUgmnFR1AmE2RTKVoTKUkbpYm1o5x56io3bRhucIC5u2bkJ-jsrIk8szzkYVrOXRGxEKP0DlToLa9dzi0OLih-5iDFXpLHWdpK47qWs6QG_37ywzs8ZfR49BMfuRwIrd3Ui2ontb0f-ylQF6vVOrTrsIjkZMGxbbtaYJh0FRuUwTPctq3k_FeArxKlkMkDwwgIO1HD5pL793TN1KAGMcffE_Fv8S3aNgtJBNUx-jo81qG14lQLSxQ3RbzuUQ3RlPzqazYbcT0nU2vvgFOjIG8g |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hsp90+up-regulates+PD-L1+to+promote+HPV-positive+cervical+cancer+via+HER2%2FPI3K%2FAKT+pathway&rft.jtitle=Molecular+medicine+%28Cambridge%2C+Mass.%29&rft.au=Zeng%2C+Jie&rft.au=He%2C+Si-Li&rft.au=Li%2C+Li-Jie&rft.au=Wang%2C+Chen&rft.date=2021-10-19&rft.issn=1528-3658&rft.eissn=1528-3658&rft.volume=27&rft.issue=1&rft.spage=130&rft_id=info:doi/10.1186%2Fs10020-021-00384-2&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1076-1551&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1076-1551&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1076-1551&client=summon |